Inclusion Criteria

Inclusion Criteria

1. Written informed consent

2. Males and females aged ≥18 years old

3. Histologically or cytologically confirmed adenocarcinoma of the pancreas

4. Locally advanced (Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas

5. Spiral CT scan demonstrating at least one pancreatic adenocarcinoma measurable lesion
according to RECIST criteria and PET scan showing metabolically active lesion (for
the last six subjects in the 15 mg/kg and the subjects in the 25 mg/kg FG-3019 dose
cohorts only)

6. Women of childbearing potential and men must use effective contraception during and
for at least 90 days following study participation. Women of childbearing potential
must have a negative Screening serum pregnancy test.

7. ECOG performance status score of 0-1

8. Life expectancy >12 weeks

9. Ability to adhere to the study visit schedule and understand and comply with all
protocol requirements and instructions from study staff

Exclusion Criteria

1. Absolute neutrophil count (ANC) <500 cells/mm3

2. Hemoglobin <10.0 g/dL

3. Platelet count <100,000 cells/mm3

4. Bilirubin >2.0 x upper limit of normal (ULN)

5. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2.5 x ULN, or
>3.5 x ULN if liver metastases are present

6. If the subject is diabetic, HbA1c >10%

7. Current pregnancy or breast feeding due to recent pregnancy

8. History of another malignancy in the past 2 years with the exception of basal cell or
squamous cell carcinoma of the skin

9. Previous chemotherapy with gemcitabine

10. Previous systemic antineoplastic agent (other than adjuvant 5-fluorouracil as
radio-sensitizer)

11. Adjuvant 5-fluorouracil within 28 days prior to Day 1

12. Major surgery within 28 days prior to Day 1 (stent placement is allowed)

13. Radiation therapy within 28 days prior to Day 1

14. Clinical evidence or any history of brain metastasis

15. Uncontrolled hypertension (systolic blood pressure [SBP] >180 mmHg or diastolic blood
pressure [DBP] >105 mmHg)

16. New York Heart Association Class III or IV congestive heart failure

17. History of allergic or anaphylactic reaction to human, humanized, or chimeric
monoclonal antibodies

18. Current clinical or laboratory evidence of active infection requiring antibiotic or
antiviral therapy

19. Active major gastrointestinal bleeding

20. Full-dose heparin therapy within 28 days prior to Day 1

21. Participation in studies of investigational products within 42 days prior to Day 1

22. Clinically significant and uncontrolled medical condition considered a high risk for
participation in an investigational study or a likelihood that the subject will be
unable to comply with protocol requirements and complete the trial (e.g., emphysema
requiring supplemental oxygen, poorly controlled arrhythmia, psychiatric illness,
Alzheimer's disease)

23. Current abuse of alcohol or drugs